Robert Ward

NPI: 1144309717
Total Payments
$153,835
2024 Payments
$5,158
Companies
10
Transactions
72

Payment Breakdown by Category

Consulting$132,443 (86.1%)
Travel$15,561 (10.1%)
Other$4,730 (3.1%)
Food & Beverage$1,101 (0.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $132,443 34 86.1%
Travel and Lodging $15,561 22 10.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,730 1 3.1%
Food and Beverage $1,101 15 0.7%

Top Paying Companies

Company Total Records Latest Year
Shire North American Group Inc $62,192 38 $0 (2018)
Janssen Research & Development, LLC $47,999 10 $0 (2024)
PFIZER INC. $12,125 6 $0 (2019)
Mallinckrodt LLC $7,556 3 $0 (2018)
Regeneron Pharmaceuticals, Inc. $7,000 6 $0 (2023)
Organon LLC $4,890 1 $0 (2023)
American Regent $4,878 4 $0 (2019)
Shionogi Inc $4,158 2 $0 (2024)
Janssen Global Services, LLC $1,620 1 $0 (2021)
Takeda Pharmaceuticals U.S.A., Inc. $1,417 1 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2024 $5,158 3 Shionogi Inc ($4,158)
2023 $11,890 7 Regeneron Pharmaceuticals, Inc. ($7,000)
2022 $16,500 3 Janssen Research & Development, LLC ($16,500)
2021 $30,369 6 Janssen Research & Development, LLC ($28,749)
2020 $3,167 2 Janssen Research & Development, LLC ($1,750)
2019 $6,878 5 American Regent ($4,878)
2018 $43,604 20 Shire North American Group Inc ($26,149)
2017 $36,269 26 Shire North American Group Inc ($36,043)

All Payment Transactions

72 individual payment records from CMS Open Payments — Page 1 of 3

Date Company Product Nature Form Amount Type
12/13/2024 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $1,000.00 General
08/01/2024 Shionogi Inc Fetroja (Drug) Consulting Fee Cash or cash equivalent $4,130.00 General
Category: Infections and Infectious Diseases
08/01/2024 Shionogi Inc Fetroja (Drug) Travel and Lodging Cash or cash equivalent $28.14 General
Category: Infections and Infectious Diseases
07/21/2023 Organon LLC Consulting Fee Cash or cash equivalent $4,890.00 General
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $2,750.00 General
Category: OPHTHALMOLOGY
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $1,750.00 General
Category: OPHTHALMOLOGY
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $1,125.00 General
Category: OPHTHALMOLOGY
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $625.00 General
Category: OPHTHALMOLOGY
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $500.00 General
Category: OPHTHALMOLOGY
03/20/2023 Regeneron Pharmaceuticals, Inc. EYLEA HD (Biological) Consulting Fee Cash or cash equivalent $250.00 General
Category: OPHTHALMOLOGY
05/10/2022 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $5,500.00 General
04/27/2022 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $9,125.00 General
02/18/2022 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $1,875.00 General
10/05/2021 Janssen Global Services, LLC Consulting Fee Cash or cash equivalent $1,620.00 General
09/13/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $6,333.00 General
06/24/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $2,958.00 General
06/07/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $3,500.00 General
04/09/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $14,458.00 General
03/24/2021 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $1,500.00 General
12/28/2020 Janssen Research & Development, LLC Consulting Fee Cash or cash equivalent $1,750.00 General
01/11/2020 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $1,417.00 General
12/03/2019 American Regent INJECTAFER (Drug) Consulting Fee Cash or cash equivalent $3,167.26 General
Category: Anemia
10/18/2019 American Regent INJECTAFER (Drug) Consulting Fee Cash or cash equivalent $476.60 General
Category: Anemia
10/07/2019 PFIZER INC. ELIQUIS (Drug) Consulting Fee Cash or cash equivalent $2,000.00 General
Category: CARDIOVASCULAR;METABOLIC DISEASE
05/10/2019 American Regent INJECTAFER (Drug) Consulting Fee Cash or cash equivalent $617.30 General
Category: Anemia

About Robert Ward

Robert Ward is a Neonatal-Perinatal Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144309717.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Ward has received a total of $153,835 in payments from pharmaceutical and medical device companies, with $5,158 received in 2024. These payments were reported across 72 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($132,443).

Practice Information

  • Specialty Neonatal-Perinatal Medicine
  • Location Salt Lake City, UT
  • Active Since 11/03/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 2080N0001X
  • Entity Type Individual
  • NPI Number 1144309717

Products in Payments

  • ELIQUIS (Drug) $11,899
  • EYLEA HD (Biological) $7,000
  • OBIZUR (Biological) $5,627
  • INJECTAFER (Drug) $4,878
  • Fetroja (Drug) $4,158

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Neonatal-Perinatal Medicine Doctors in Salt Lake City